How to Give Atropine IV
For symptomatic bradycardia in adults, administer atropine 0.5 mg intravenously as an initial bolus, which can be repeated every 3-5 minutes up to a maximum total dose of 3 mg (complete vagal blockade occurs at approximately 0.03-0.04 mg/kg). 1, 2, 3
Dosing Algorithm by Clinical Indication
For Symptomatic Bradycardia (Heart Rate <50 bpm with hypotension, ischemia, or ventricular arrhythmias):
- Initial dose: 0.5-1 mg IV push 1, 2
- Repeat: Every 3-5 minutes as needed 2
- Maximum total dose: 3 mg (or 0.03-0.04 mg/kg) 1, 2
- Onset of action: Peak effect within 3 minutes 1
For Cardiac Arrest/Asystole:
- Initial dose: 1 mg IV push 1, 2
- Repeat: Every 3-5 minutes during CPR 1, 2
- Maximum cumulative dose: 3 mg total 2
For Pediatric Patients:
- Dose: 0.02 mg/kg IV/IO 4
- Minimum single dose: 0.1 mg (critical to avoid paradoxical bradycardia) 4
- Maximum single dose: 0.5 mg (child), 1.0 mg (adolescent) 4
- Repeat: Every 5 minutes to maximum 1 mg (child) or 2 mg (adolescent) 4
For Organophosphate/Carbamate Poisoning:
- Initial dose: 2-3 mg IV (adults) 2
- Pediatric: 0.05 mg/kg IV 4
- Repeat: Every 20-30 minutes, doubling dose every 5 minutes until full atropinization achieved 5
- Note: Much larger cumulative doses often required for this indication 5
Critical Administration Technique
Route: Intravenous push only for emergency indications 1, 3
- Administer as rapid IV bolus over 15 seconds for optimal effect 6
- Ensure IV line patency before administration
- Do not dilute standard concentrations (0.4 mg/mL or 1 mg/mL) 3
Common Pitfalls to Avoid
The Paradoxical Bradycardia Trap:
Never give doses <0.5 mg IV - this can paradoxically worsen bradycardia and AV conduction through central vagal stimulation or peripheral parasympathomimetic effects 1. This is one of the most important safety considerations.
Route-Specific Risks:
- Avoid IM administration in acute settings - associated with paradoxical slowing and unpredictable absorption 1, 6
- If IV access unavailable in cardiac arrest, endotracheal administration requires 2-3× the IV dose (0.04-0.06 mg/kg in children) 4
Dose-Related Adverse Effects:
Higher initial doses (≥1 mg) or cumulative doses >2.5 mg over 2.5 hours increase risk of: 7
- Ventricular tachycardia/fibrillation
- Sustained sinus tachycardia (which can worsen myocardial ischemia)
- Toxic psychosis, hallucinations, fever 1
When NOT to Use Atropine
Contraindications (Class III): 1
- Type II second-degree AV block or third-degree AV block with wide QRS (infranodal block) - atropine may paradoxically increase sinus rate while worsening the block 1, 2
- Asymptomatic sinus bradycardia >40 bpm without hypoperfusion 1
- Patients on beta-blockers with refractory bradycardia (consider glucagon instead) 8
Special Populations
Coronary Artery Disease:
Limit total dose to 0.03-0.04 mg/kg to minimize risk of tachycardia-induced ischemia 3. The resulting sinus tachycardia can extend infarct size and precipitate ventricular arrhythmias 1.
When Atropine Fails:
If no response after appropriate atropine dosing: 2, 9
- Consider transcutaneous pacing (may require sedation due to pain)
- Epinephrine infusion (2-10 mcg/min) or push-dose epinephrine
- Dopamine infusion (5-20 mcg/kg/min)
- Transvenous pacing for definitive management
Monitoring Requirements
After administration, continuously monitor: 1
- Heart rate and rhythm (expect increase within 3 minutes)
- Blood pressure
- Signs of excessive tachycardia or ischemia
- Mental status (for CNS toxicity with repeated doses)
- Pupil size and accommodation (anticholinergic effects)
The most recent 2025 AHA guidelines 9 emphasize addressing underlying causes of bradycardia (hypoxia, hypothyroidism, medications, electrolyte abnormalities) while simultaneously administering atropine, as bradycardia may be difficult to resolve without correcting the root cause.